Rivus Pharmaceuticals Raises $132M for Cardio-Metabolic Disorders

Rivus Pharmaceuticals Inc. has closed a $132 million Series B funding round.

He was led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital.

The funding will further support the clinical development of the lead candidate HU6, a first-in-class controlled metabolic accelerator (CMA) designed to treat cardiometabolic disease by addressing obesitythe main driver of the disease.

“We have an exceptional group of investors who share our vision of bringing a new class of treatment to patients with obesity and cardiometabolic disease,” said Allen Cunningham, president and CEO of Rivus Pharmaceuticals.

“Following encouraging data from our Phase 2a clinical trial in obese patients, this funding allows us to advance the development of HU6 and a pipeline of controlled metabolic accelerators to address a range of cardiometabolic diseases.”

About CMA Rivus Pharmaceuticals

Nearly half of American adults live with cardiometabolic disease, conditions that negatively affect a person’s health and quality of life. Obesity is a common driver of cardiometabolic disease, but weight loss through lifestyle modification remains a challenge for many patients.

Rivus Pharmaceuticals’ CMA is designed to safely use mitochondrial uncoupling, a natural process that regulates and dissipates energy, to selectively reduce fat throughout the body.

Although numerous approaches are being explored to reduce energy intake in obesity, CMAs are unique in their focus on increasing energy expenditure, thereby avoiding the loss of skeletal muscle mass seen with other therapeutic agents.

Published data

Earlier this year, Rivus Pharmaceuticals published data from a phase 2a metabolic study that studied lead candidate HU6 in obese participants. The study provided proof-of-concept that CMAs have the potential to treat not only obesity but also a number of cardiometabolic diseases, including heart failure with preserved ejection fraction (HFpEF), type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)/non-alcoholic fatty liver disease (NAFLD). steatohepatitis (NASH).

During an eight-week study, the company found that HU6 demonstrated significant reductions in liver, visceral and total body fat while preserving skeletal muscle mass, all without changing diet or exercise. Weight loss was increased in patients with elevated HbA1c.

Reduction in liver fat was 30%-40% at various doses and will be further determined in a longer phase 2b obesity study.

Patients treated with HU6 saw improvements in key cardiovascular and metabolic health measures, including glycemic control, glycated albumin and HbA1c, reductions in blood pressure and markers of inflammation.

Phase 1 and 2a metabolic data showed that HU6 was well tolerated at all dose levels with no serious adverse events (SAEs) or deaths.

Rivus Pharmaceuticals recently initiated a Phase 2a study in patients with obesity and heart failure with preserved ejection fraction (HFpEF) and plans to initiate a Phase 2b study in obesity, including a subset of participants with obesity and type 2 diabetes, in 2023.

About HU6 and CMA

HU6 is a CMA that provides a new, balanced approach to activating mitochondrial uncoupling, the body’s natural process by which the body produces heat. By withdrawing protons from the mitochondrial intermembrane space, CMAs cause increased oxidation of sugars and fats while maintaining the same basal production of adenosine triphosphate (ATP). Activation of this process leads to a reduction of accumulated fat and sugar in the body. Rivus Pharmaceuticals Raises $132M for Cardio-Metabolic Disorders

Back to top button